AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06093360 — intervention group
Intervention type: PROCEDURE
Intervention: flapless surgery
Description: Implant-supported restorations were unscrewed and modified if necessary (biofilm control). All the restorations were relocated at the end of each intervention session. After local anesthesia, a periodontal ultrasonic stainless-steel tip was used for supra- and sub-mucosal mechanical debridement. Next, a Columbia 4R/4L curette was used around the implant in a circular motion until a bone exposure of 2-3 mm was achieved. Mucosal curettage was simultaneously performed to remove the granulation tissue. After obtaining access to the implant surface, ultrasonic instrumentation was repeated and air polishing with an erythritol powder was applied submucosally with the aim of a periodontal probe. Hydrogen peroxide 3% was used to irrigate the implant surface for 2 minutes, followed by a rinse with saline. Oral hygiene instructions were given. Systemic antibiotics, when prescribed, were metronidazole or azithromycin
Study NCT00001082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: 500 mg tablet taken orally daily
Study NCT00001082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil
Description: 120 mg tablet taken orally daily
Study NCT00001082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil placebo
Description: Oral placebo tablet taken daily
Study NCT03099356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
Study NCT03099356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus 4 mg, PO, days 1-28
Study NCT03486639 — intervention group
Intervention type: OTHER
Intervention: IPSS questionnaire
Description: IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
Study NCT04215328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixed-Meal
Description: Per 250ml bottle: 220 calories, protein 9g, carbohydrate 33g (15g sugar), fat 6g, sodium 190mg, potassium 390mg; 500mLs by tube daily in 4 doses
Study NCT04215328 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Electrolyte Solution
Description: Electrolyte Solution 500mLs by tube daily in 4 doses
Study NCT02488239 — intervention group
Intervention type: DEVICE
Intervention: CRT-P indicated patients
Description: Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
Study NCT01891773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaled steroids in school.
Description: Morning dose of inhaled steroids given in school by school nurse instead of at home.
Study NCT01669460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Bull™ Sugar-Free Drink
Description: Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
Study NCT03334058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-113
Description: human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
Study NCT00896688 — intervention group
Intervention type: PROCEDURE
Intervention: cervical medial branch blocks using the Quincke spinal needle
Description: #25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
Study NCT01121601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic surgery of resection
Description: after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
Study NCT01121601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hepatic surgery of resection
Description: this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
Study NCT02458664 — intervention group
Intervention type: GENETIC
Intervention: Genetic analysis on tumor kept in tumor bank
Study NCT03734861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreatheSmart System
Description: * BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~* HeroTracker sensor that counts dosage and monitors real-time medication adherence~* CoheroConnect provider portal that allows the Investigator to monitor adherence
Study NCT03734861 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
Study NCT04814160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixture of bioactive glass and autogenous bone graft
Description: bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
Study NCT04814160 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous bone graft
Description: bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
Study NCT01506622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of propofol
Description: Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
Study NCT01506622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of fentanyl
Description: Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
Study NCT01506622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of saline
Description: Saline will be administered to control group at the end of anesthesia.
Study NCT02482922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise & Dietary Supplement
Study NCT00367133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Group
Description: Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
Study NCT00367133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg triamcinolone acetonide
Description: Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Study NCT00367133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4mg triamcinolone acetonide
Description: 4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
Study NCT03893123 — intervention group
Intervention type: OTHER
Intervention: Observational study, prostate cancer is outcome of interest
Description: Observational study
Study NCT02336074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination Antiretroviral Therapy (cART)
Description: Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
Study NCT02336074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Antiretroviral Therapy (cART)
Description: Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
Study NCT02336074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
Study NCT02336074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
Study NCT02336074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate.
Study NCT02336074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv (ChAd)
Description: Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
Study NCT02336074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv (MVA)
Description: Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
Study NCT01252953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: tablet, 100mg daily
Study NCT04062604 — intervention group
Intervention type: OTHER
Intervention: surgery
Description: surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
Study NCT01252953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo anacetrapib
Description: tablet, 1 tablet daily
Study NCT03264521 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
Study NCT02464657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I.
Study NCT02464657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
Study NCT02464657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
Study NCT02464657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solu-medrol
Description: Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
Study NCT02464657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
Study NCT01619241 — intervention group
Intervention type: OTHER
Intervention: PET/CT
Description: F-18 FLT PET/CT
Study NCT03781102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 16-Week Diabetes Prevention Program for Mothers and Children
Description: The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
Study NCT03781102 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 16-Week Diabetes Prevention Program for Mothers and Children
Description: The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
Study NCT03034356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Anticonvulsant drug
Study NCT03034356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04285268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV or SC
Study NCT04285268 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04285268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03459235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life
Description: Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
Study NCT02125981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Limaprost
Description: taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
Study NCT02125981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking placebo drug
Study NCT01803594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill Oil
Description: Neptune Krill Oil Gold
Study NCT01803594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Jarrow Formulas
Study NCT01803594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Natures Way
Study NCT01803594 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy phospholipids
Description: PC700 manufactured by Fonterra
Study NCT01803594 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control shake without dietary supplements
Study NCT02993432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter filled to 80cc
Description: A Foley catheter is inserted through the cervix and filled to 80cc
Study NCT02993432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prostaglandin of the clinician's choice
Description: Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
Study NCT01307618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NA17.A2 Peptide Vaccine
Description: Given SC or ID
Study NCT01307618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant MAGE-3.1 Antigen
Description: Given SC or ID
Study NCT01307618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interleukin-12
Description: Given SC or ID
Study NCT01307618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 Antigen
Description: Given SC or ID
Study NCT01307618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01356056 — intervention group
Intervention type: DEVICE
Intervention: Kinesia HomeView
Description: Quantifies motor symptom severity in the home
Study NCT04714580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Fun Program
Description: This program permits the operators to propose different activities, by following the needing of the children. As the name of this program suggests, all the activities involve an animal description, and ask the children to move like this animal, in a proper, correct and supervised way.
Study NCT03050463 — intervention group
Intervention type: PROCEDURE
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo fMRI related tasks
Study NCT03050463 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02480660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
Study NCT03227276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine
Description: 2 tablets to be taken 3 times a day after meals
Study NCT03227276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 2 tablets to be taken 3 times a day after meals
Study NCT03110627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDD ICD (experimental group)
Description: Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications.
Study NCT03110627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single chamber VVI ICD (control group)
Description: Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications.
Study NCT04618900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus floor elevation with a grafting material
Description: The use of grafting material for sinus floor elevation
Study NCT04618900 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sinus floor elevation with a grafting material
Description: The use of grafting material for sinus floor elevation
Study NCT03218787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.
Study NCT03218787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: 3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care.
Study NCT05281120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level mechanical vibrations WITH vertical sinusoidal acceleration
Description: Small platform designed to induce vertical, sinusoidal acceleration.
Study NCT05281120 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low-level mechanical vibrations WITHOUT vertical sinusoidal acceleration
Description: Small platform designed to NOT induce vertical, sinusoidal acceleration
Study NCT01949324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Description: Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
Study NCT01949324 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham surgery for Sham arm
Study NCT01949324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NT-501 Implant
Description: NT-501 encapsulated cell implant
Study NCT01949324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT-501 Implant procedure
Description: Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
Study NCT01062490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14 g/m2/d, day -6 to -4
Study NCT04143516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18-F]- FDG - PET
Description: Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion